Simeon George has bought stock on 9 days since Sep 2018
Director at CRISPR Therapeutics AG, and 5 other companies
SEC CIK 0001595117 · Filings on SEC.gov ↗
Simeon George's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
Every filing
10 filings since Sep 2018, newest first
CRISPR Therapeutics AG
Director
ADARx Pharmaceuticals, Inc.
Director
Crispr Therapeutics AG
Director
Nkarta, Inc.
Director
Design Therapeutics, Inc.
Director and 10% owner
Turning Point Therapeutics, Inc.
Director
Principia Biopharma Inc.
Director
Turning Point Therapeutics, Inc.
Director
Turning Point Therapeutics, Inc.
Director
Principia Biopharma Inc.
Director and 10% owner
About Simeon George
Simeon J. George, M.D., M.B.A. is a Director on the Board of CRISPR Therapeutics AG (CRSP), a position he has held since April 2015.( As CEO and Managing Partner of SR One Capital Management, LP, a transatlantic biotech venture capital firm he co-founded following its 2020 spin-out from GlaxoSmithKline, George oversees investments in innovative biotechs, including early funding for CRSP when it was a nascent startup.(
George's career highlights include leading SR One’s investments in Principia Biopharma (acquired by Sanofi for $3.7B), Turning Point Therapeutics, Progyny, Arcellx, and co-founding Nkarta (NKTX) and Design Therapeutics (DSGN), where he serves on the boards.( Earlier, he worked in management consulting at Bain & Company and investment banking at Goldman Sachs, following his education: M.D. and M.B.A. from the University of Pennsylvania (Perelman School of Medicine and Wharton School), and B.A. in Neuroscience from Johns Hopkins University (Phi Beta Kappa).(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.